**Ursolic acid inhibits proliferation and induces apoptosis by inactivating Wnt/β-catenin signaling in human osteosarcoma cells**

RAN-XI ZHANG\(^{1,2}\), YANG LI\(^{1,3}\), DONG-DONG TIAN\(^{1,2}\), YANG LIU\(^{2}\), WU NIANG\(^{1,2}\), XIANG ZOU\(^{1,2}\), QIAN-ZHAO CHEN\(^{1,3}\), LIN-YUN ZHOU\(^{1,3}\), ZHONG-LIANG DENG\(^{2}\) and BAI-CHENG HE\(^{1,3}\)

\(^{1}\)Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing Medical University; \(^{2}\)Department of Orthopaedics, The Second Affiliated Hospital of Chongqing Medical University; \(^{3}\)Department of Pharmacology, School of Pharmacy, Chongqing Medical University, Chongqing, P.R. China

Received June 9, 2016; Accepted September 1, 2016

DOI: 10.3892/ijo.2016.3701

**Abstract.** Although multiple chemotherapeutic agents have been used for osteosarcoma (OS) treatment, their mechanisms need further study. Ursolic acid (UA), a pentacyclic triterpenoid, can reduce cell proliferation and induce apoptosis in various cancer cells, such as OS. However, the exact mechanism underlying this function remains unclear. In this study, we investigated the anti-proliferative effect of UA in human OS 143B cells and dissected the possible molecular mechanism underlying this effect. We demonstrated that UA can reduce cell proliferation, induce apoptosis and arrest cell cycle in 143B cells, as well as inhibit OS tumor growth in a mouse xenograft model. Using a luciferase reporter assay, we found that the Wnt/β-catenin signaling is inhibited by UA in 143B cells. Correspondingly, the expression level and nuclear translocation of β-catenin are both decreased by UA. Exogenous expression of β-catenin attenuates the anticancer effect of UA in 143B cells, while knockdown of β-catenin enhances this effect. UA increases the expression level of p53 in a concentration-dependent manner, and inhibition of p53 reduces the anticancer effect of UA in 143B cells. Moreover, inhibition of p53 partly reverses the UA-induced downregulation of β-catenin, as do the targets of Wnt/β-catenin signaling, such as c-Myc and cyclin D1. Our findings indicated that UA can inhibit the proliferation of 143B OS cells through inactivation of Wnt/β-catenin signaling, which may be mediated partly by upregulating the expression of p53.

**Introduction**

Osteosarcoma (OS) is a prevalent primary malignancy of bone and mainly occurs in adolescents and children (1). OS is often located in the metaphyses of long bone where it grows rapidly, including the proximal tibia, proximal humerus and distal femur (2,3). OS is commonly marked by aggressive proliferation, high rate of recurrence, and early systemic metastasis, especially the metastasis to the lung (1-3). With surgery combined with the treatment of chemotherapy drugs, such as cisplatin, doxorubicin and methotrexate, a gradual improvement has been made to increase the long-term survival rate (4). However, the current therapeutic regimen remains undesirable and often results in chemoresistance (5). Hence, there is an urgent clinical need to explore new antitumor reagents for OS. The traditional Chinese medicine, especially the herb-derived components, has received increasing attention as a source of novel pharmacologics. Better curative effects have been noted when herb-derived components are combined with the traditional chemotherapy agents in treatment for multiple cancers (6-8).

Ursolic acid (UA), one of these potential compounds, is a pentacyclic triterpenoid. It has been identified in medical herbs and edible plants, including loquat leaf and rosemary. Previous studies have revealed that UA can suppress proliferation and induce apoptosis in various tumor cells, such as prostate, lung and pancreas (6,9,10). Furthermore, UA has been reported to be able to inhibit tumor progression (11), induce tumor cell differentiation (12) and inhibit angiogenic activity (13). UA was also found to be chemopreventive in different animal models (13,14), suppress tumor invasion (10), and sensitize the orthotopically implanted pancreatic tumors to gemcitabine (6). It has been confirmed that UA can modulate various cancer-related signals. For example, UA interferes with DNA replication (15), activates caspases (16) and c-Jun N-terminal kinases (JNK) (7), downregulates anti-apoptotic genes, such as COX-2, NO synthase and protein tyrosine kinase (15). UA has been shown to increase the expression of p53, while decreasing that of NF-κB, and this effect was differentiated in tumor cells as compared to normal cells, which did not exhibit this response to UA (17). Moreover, UA was found to induce cell cycle arrest at G1 phase in tumor cells (18). Recently, it was reported that UA was effective in inducing apoptosis of MG-63 OS *in vitro* (19). However, the exact mechanism underlying these effects of UA in OS remains unknown.

**Correspondence to:** Professor Bai-Cheng He, Department of Pharmacology, School of Pharmacy, Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong, Chongqing 400016, P.R. China

E-mail: hebaicheng99@yahoo.com; 894704897@qq.com

**Key words:** ursolic acid, osteosarcoma, proliferation inhibition, Wnt/β-catenin, p53
It has been verified that Wnt/β-catenin signaling is a pivotal factor in modulating proliferation, differentiation and motility of cells (20). Aberrant activation of Wnt/β-catenin signaling was found in a number of bone tumors (21,22). Former studies indicated that several ligands, receptors and co-receptors of Wnt maintain high expression levels in OS cells, whereas Wnt inhibitors are decreased (23,24). Therefore, a number of novel antitumor strategies for OS have been developed by targeting the Wnt/β-catenin signaling (22). Although UA shows valid antitumor activities in a variety of tumors, it still remains unclear whether the mechanism underlying the antitumor activity of UA on OS cells is implicated with the inhibition of Wnt/β-catenin signaling.

In the present study, we evaluated the inhibitory effect of UA on the proliferation of human OS cells, and dissected the possible mechanisms underlying these effects. We found that UA could inhibit the proliferation and induce apoptosis in 143B OS cells. The inhibitory effect of UA may be mediated by inactivating Wnt/β-catenin signaling through upregulating p53 at least.

**Materials and methods**

**Chemical preparations and cell lines.** UA, with a purity of 98.6%, was obtained from Xi’an Hao-Xuan Bio-Tech Co., Ltd. (Xi’an, China). The human OS cell line 143B was obtained from the American Type Culture Collection (Manassas, VA, USA). Pifithrin-α (PFT-α) was purchased from Selleck Chemicals (Houston, TX, USA). UA and PFT-α were dissolved with dimethyl sulfoxide (DMSO) for experiments in vitro. For in vivo experiments, UA was suspended in 0.4% carboxymethylcellulose sodium. The primary antibodies rabbit anti-human STAT3 and p-STAT3 were obtained from Abcam (Cambridge, MA, USA), and other antibodies were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Cells were cultured with DMEM (containing 10% FBS, obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA), and other antibodies were purchased from Abcam (Cambridge, MA, USA), and other antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Cells were cultured with DMEM (containing 10% FBS, 100 U/ml of penicillin and 100 µg/ml of streptomycin). Cells were incubated in 5% CO₂ and 37°C.

**Cell viability assay.** Cell viability was determined with Cell Counting Kit-8 (CCK-8). In brief, 143B cells were seeded in 96-well plates with a final density of 3×10⁴ cells/well and incubated for 24 h. The cells were treated with different concentrations of UA, recombinant adenovirus or DMSO for 24, 48 and 72 h. Thereafter, 10 µl of CCK-8 (Dojindo Laboratories, Kumamoto, Japan) were added into each well and incubated for another 4 h. The absorbance was determined at 450 nm with a microplate reader. Each test was conducted in triplicate.

**Clonogenic assay.** The clonogenic assay was employed to determine the ability of cells in a given population to undergo unlimited division and form colonies. This assay was carried out as described (25). Briefly, cells were treated with different concentrations of UA for 24 h and then replated with 2,000 cells/well into 6-well plates. Then cells were maintained up to 14 days until colonies were formed. Plates were washed gently with PBS and incubated with 0.25% crystal violet formalin solution at room temperature for 20 min. Each test was conducted in triplicate.

**Flow cytometric analysis for cell cycle and apoptosis.** The 143B cells were plated into a 6-well plate. For cell cycle assay, cells were treated with different concentrations of UA or DMSO for 24 h. Then cells were harvested, washed with cold (4°C) PBS, fixed with cold (4°C) 70% ethanol. Finally, cells were suspended in 300 µl PBS, and incubated with propidium iodide (PI) (20 mg/ml) and RNase (1 mg/ml) for 30 min. The cells were detected with fluorescence-activated cell sorting (FACS) subsequently. The DNA contents were analyzed with ModFit LT software. For apoptosis analysis, cells were treated with UA for 24 h. Then the cells were collected and washed with cold (4°C) PBS, incubated with Annexin V-FITC/PI following the instruction of the kits (KeyGen, Nanjing, China). Finally, the processed cells were sorted with FACS and the data were analyzed with FlowJo. Each test was conducted in triplicate.

**Construction of recombinant adenoviruses.** Recombinant adenoviruses expressing β-catenin (AdBC) and small interfering RNA fragments targeting β-catenin (AdsiBC) were constructed with AdEasy system (26), respectively. AdBC was tagged with green fluorescence protein and AdsiBC was tagged with red fluorescence protein. The adenovirus-expressing green fluorescence protein (AdGFP) only was used as vector control.

**Western blotting.** Subconfluent 143B cells were plated in a 6-well plate and treated with pre-designated concentrations of UA or DMSO. For total cellular protein or tissue protein, cells and tissues were harvested and lysed using ice-cold lysis buffer at pre-designated time-points. For subcellular fractionation, the protein was extracted with NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Inc., Rockford, IL, USA) based on the manufacturer’s instructions. The lysates were boiled for 10 min, subjected to SDS-PAGE separation and transferred to polyvinylidene difluoride (PVDF) membranes. Then the membranes were blotted with corresponding primary antibodies, followed by incubation with HRP-labelled second antibodies. Finally, the bands of target proteins were developed with the SuperSignal West Pico Substrate (Pierce Biotechnology, Inc.). All assays were performed in triplicate.

**Reverse transcription-polymerase chain reaction (RT-PCR) analysis.** Cells were treated with indicated concentrations of UA in T-25 culture flasks. Total RNA was extracted with TRIzol reagents (Invitrogen, Carlsbad, CA, USA) and transcribed to cDNA templates with RT reaction at pre-designated time-points. Then, the cDNA templates were used to detect the expression levels of target genes by PCR. The primer sequences are available upon request. All assays were performed in triplicate.

**Luciferase reporter assay.** Cells were seeded in T-25 culture flasks and transfected with β-catenin/TCF-4 luciferase reporter (pTOP-luc) 3 µg per flask with Lipofectamine 2000 (Invitrogen) (25,27). The cells were replated into a 24-well plate 16 h after transfection, and then treated with indicated concentrations of UA or DMSO. The cell lysates were subjected to luciferase assays with luciferase assay kit (Promega Corp.,
Madison, WI, USA) 24 h after treatment. All assays were
performed in triplicate.

Xenograft model of human OS. The animal experi-
ment was approved by the Institutional Animal Care
and Use Committee (IACUC) of Chongqing Medical
University. Athymic nude mice (female, 4-6 weeks old,
5/group) were from the Animal Center of Chongqing Medical
University (Chongqing, China). The 143B cells were collected
and re-suspended in cold PBS (4˚C) to 2x10^7 cells/ml. Then
cells in 100 µl of PBS were injected subcutaneously into the
right flanks of the nude mice. Three days after injection, the
athymic nude mice were given UA (100 and 200 mg/kg) or
solvent by intragastric administration once a day for 4 weeks.
The mice were sacrificed and the tumor samples were photo-
graphed and harvested for histological evaluation.

Immunohistochemical staining and histological evaluation.
Retrieved tumor masses were fixed with 4% paraformaldehyde
and embedded with paraffin, respectively. Serial sections
were deparaffinized and rehydrated in a gradient fashion.
Then the slides were stained with hematoxylin and
eosin (H&E) (25). For immunohistochemical staining,
the slides were further processed for antigen retrieval, and
incubated with proliferating cell nuclear antigen (PCNA)
antibody (1:100 dilution), or Wnt/β-catenin antibody (1:50
dilution) or isotype IgG as control. Finally, the slides were
incubated with streptavidin-labelled secondary antibodies
and visualized with 3,3'-diaminobenzidine (DAB) tetrahydro-
chloride reagent (25,27).

Statistical analysis. All quantitative tests were performed
in triplicate. Statistical analyses were performed with
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla,
CA, USA). All measurement results were expressed as
mean ± SD. Statistical significances between the two groups
were determined with Student's t-test. p<0.05 was considered
statistically significant.
Results

UA inhibits cell proliferation in 143B cells. To identify whether UA may serve as an effective chemotherapeutic reagent for human OS, the CCK-8 assay was employed to validate the anti-proliferative effect of UA in 143B cells. We found that the proliferation of 143B cells can be inhibited markedly by UA in a time- and concentration-dependent manner (Fig. 1A). Cell cycle analyses indicated that UA induces cell cycle arrest at G1 phase in 143B cells (Fig. 1B). We further checked the biomarkers of G1 arrest. The results indicated that UA inhibited the expression of cyclin-dependent kinase 2 (CDK2), CDK4 and CDK6 (Fig. 1C). Moreover, UA effectively suppresses the protein level of PCNA (Fig. 1C), an indicator for the status of proliferation (28). We further checked whether UA can affect the long-term colony formation ability in human OS cells. Our results illustrated that UA concentration-dependently inhibits the colony formation in 143B cells (Fig. 1D). The above results showed that UA is capable of inhibiting cell proliferation in 143B cells.

UA induces apoptosis in 143B cells. Next, we determined whether apoptosis occurs in human OS cells with the treatment of UA. 143B cells were treated with different concentrations of UA for 24 or 48 h. Then cells were analyzed with flow cytometric assay or lysed for western blotting. The results showed that UA can increase the apoptotic cell rate (Fig. 2A), enhance the protein level of Bad and cleaved caspase-3, and reduces the level of Bcl-2 concentration-dependently (Fig. 2B). According to the above results, UA can induce apoptosis in OS cells.

UA inhibits the growth of OS tumor in nude mice. We next assessed the antitumor activity of UA in vivo with a well-established xenograft OS model (27). The results showed that tumor masses in UA-treated group are smaller than those in control group, and UA inhibits the tumor growth significantly compared with control group (Fig. 3A and B). Subsequently, histologic assay was conducted to evaluate the xenograft samples. H&E staining results revealed that more necrotic cells occur in UA-treated groups than that of the control group (Fig. 3C). Furthermore, the expression of PCNA was markedly decreased in UA-treated groups (Fig. 3D), which was consistent with our data in vitro. In addition, we evaluated tumor tissue at molecular level and found that p53 was strongly elevated by UA, while β-catenin, NF-κB and the phosphorylation of STAT3 were decreased (Fig. 3E). These data implied that UA may suppress the growth of OS via β-catenin and inflammatory signaling. Collectively, these in vivo results supported that UA may be a potential antitumor reagent for human OS.

UA suppresses Wnt/β-catenin signaling in 143B cells. Cell proliferation is well regulated by multiple signaling pathways. With luciferase reporter assay, we found that the transcriptional activity of β-catenin/TCF-4 reporter was effectively reduced by UA (Fig. 4A). Given that the stabilization and nuclear translocation of β-catenin are critical events in the activation of Wnt/β-catenin signaling (27), we employed western blotting assay to check whether UA can decrease the level of β-catenin in the whole cell, cytoplasm, and nucleus. The results indicated that UA decreases the protein level of β-catenin not only in the nucleus, but also in the cytoplasm and the whole cells (Fig. 4B). Moreover, we checked the level of downstream targets in Wnt/β-catenin signaling. The results showed that the expression of c-Myc and cyclin D1 were both decreased by UA concentration-dependently (Fig. 4C). The immunohistochemical results showed
that β-catenin positive cells were reduced with UA treatment dose-dependently (Fig. 4D). These results suggested that the anti-proliferative effects of UA in OS cells may be associated with the suppression of Wnt/β-catenin signaling.

Wnt/β-catenin partly mediates the anti-proliferative effect of UA in 143B cells. To investigate the role of Wnt/β-catenin signaling in the anti-proliferative effect of UA in 143B cells, we employed recombinant adenovirus to mediate the exogenous expression or knockdown for β-catenin. With CCK-8 assay, we found that exogenous expression of β-catenin attenuated the anti-proliferative effects of UA, while knockdown of β-catenin enhanced this function of UA in 143B cells (Fig. 5A). FACS analysis results indicated that overexpression of β-catenin attenuated the G1 phase arrest induced by UA in 143B cells. On the contrary, β-catenin knockdown augmented UA-induced G1 phase arrest (Fig. 5B). Thus, our data indicated that UA may exert its antitumor effects in OS cells by partly inactivating Wnt/β-catenin signaling.

UA inactivates Wnt/β-catenin signaling through upregulating p53 in 143B cells. Although inactivation of Wnt/β-catenin signaling partly mediates the anti-proliferative effects of UA in 143B cells, the mechanism on how UA regulates Wnt/β-catenin signaling remains unknown. With further research, we discovered that UA upregulated the mRNA level...
ZHANG et al: URSOLIC ACID Wnt/β-CATENIN IN OSTEOSARCOMA

of p53 (Fig. 6A), increased the protein expression level of p53 and reduced the expression of MDM2 time- and concentration-dependently (Fig. 6B). A previous study demonstrated that overexpression of p53 downregulates β-catenin in human and mouse cells (29). Therefore, we hypothesized that UA-induced inactivation of Wnt/β-catenin signaling may be mediated through the activation of p53. With western blotting assay, we found that the effects of UA on β-catenin, c-Myc and cyclin D1 were partly reversed by p53 inhibitor (PFT-α) (Fig. 6C). Furthermore, the results of CCK-8 assay also showed that PFT-α can partly attenuate the anti-proliferative effects of UA in 143B cells (Fig. 6D), which is similar with the effects of exogenous expression of β-catenin on anti-proliferative effects of UA (Fig. 5A). Our data suggested that the inactivation of Wnt/β-catenin signaling induced by UA may be mediated by upregulating p53 in OS cells.

Discussion

In this study, we demonstrated that UA may be a potential anti-proliferative drug for OS cells in vivo and in vitro. Mechanistically, we discovered that the anticancer activities of UA may be partly mediated by suppression of Wnt/β-catenin signaling through upregulating p53 at least.

OS is one of the common malignants, which accounts for the primary OS-induced mortalities. Although surgical and medical advances have been made during the past decades, the overall survival rate of patients with OS remains 60-65% (30). The present drugs used for OS chemotherapy are mainly the same as that used in 1980s, such as doxorubicin, etoposide, cisplatin, ifosfamide and high-dose methotrexate (31). Therefore, it is urgent to explore more efficient drugs or treatment regiments for OS.
Herb-derived component is becoming increasingly important in tumor therapies. For example, curcumin, sinomenine and oldenlandia were all identified to be effective anti-osteosarcoma drugs (32-34). UA was identified in wax coating of apples 100 years ago. Nowadays, UA can be extracted from many medical herbs and edible plants (35). It shows multiple pharmacological functions, such as inhibition of tumor progression, induction of cell differentiation, inhibition of angiogenic activity and control of oxidants (35). For cancer, it has been documented that UA can induce apoptosis in prostatic cancer cells (36), inhibit the proliferation of pancreatic cancer, increase the antitumor potential of gemcitabine (6), inhibit colorectal cancer angiogenesis (13), and chemoprevent the genesis, metastasis and invasion of tumor in different animal models (10,14). Recently, it was reported that UA was effective in inducing apoptosis in MG-63 OS in vitro (19). Accordingly, our data also showed that UA inhibits proliferation time- and concentration-dependently in 143B OS cells (Fig. 1); in addition, UA also induces apoptosis in 143B cells by activating caspase-3 and modulating the proteins associated with survival, such as Bad and Bcl-2 (Fig. 2). With further analysis, we proved that UA is able to inhibit the growth of OS tumor in vivo (Fig. 3). This evidence supported the conclusion that UA may be a promising natural compound for tumor therapy, such as OS at least.

As reported, UA is a multi-target natural product (37), the antitumor effects of UA may be mediated by inactivating Wnt/β-catenin, PI3K/Akt, MAPK and NF-κB signaling (12,38,39). Considering OS, the anticancer activity of UA may be associated with upregulating caspase and activating ERK, JNK, and p38 MAPK signaling (19). However, the exact mechanism underlying the antitumor effects of UA in OS still remains unclear. Wnt/β-catenin signaling is involved in the processes of maintenance of homeostasis and development by regulating cell proliferation, differentiation, migration and apoptosis, as well as keeping stem cells under pluripotent state (40). The aberrant activation of Wnt/β-catenin signaling was implicated with tumorigenic, metastasis and invasion of a variety of cancers (41), including OS. When Wnt/β-catenin signaling is activated, β-catenin accumulates in the cytoplasm
and then translocates into the nucleus, where it regulates the expression of downstream target genes to regulate the growth and survival of cells (22). Therefore, many antitumor drugs target Wnt/β-catenin signaling (27,42,43). A previous study has proved that accumulation of β-catenin in nuclear and/or cytoplasm occurred in OS cells, and the accumulation may be associated with the pathogenesis of OS (44). As Wnt/β-catenin signaling is a target of UA, we speculated that the anticancer activity of UA in 143B cells may be also associated with it. In the present study, we found that UA can inhibit the transcriptional activity of pTOP-luc reporter in 143B cells (Fig. 4A), as well as the expression of β-catenin in cytoplasm and nucleus in vitro and in vivo (Fig. 4B and D). It is noteworthy that c-Myc and cyclin D1 are downstream targets of Wnt/β-catenin (45). We found that UA can reduce the expression of c-Myc and cyclin D1 (Fig. 4C). All this evidence indicates that UA can inhibit Wnt/β-catenin signaling in 143B OS cells. Our results further demonstrated that exogenous expression of β-catenin attenuates the effects of anti-proliferation and cell cycle arrest induced by UA in 143B cells, while knockdown of β-catenin enhances these functions of UA (Fig. 5). Thus, the antitumor activities of UA in 143B OS cells may be mediated by inactivating Wnt/β-catenin signaling, but this finding alone does not reveal how Wnt/β-catenin signaling is modulated and thus
additional experiments need to be conducted to elucidate the inhibitory mechanism.

p53, a well-known tumor suppressor, is a cell cycle regulator with a transient half-life (46). The function of p53 is regulated by enhancing its transcription and post-translational stabilization to escape ubiquitin-dependent degradation (47). An earlier study reported that UA can induce apoptosis in SW480 cells by increasing p53 (48). Moreover, Wnt/β-catenin signaling can be downregulated by p53 (29,49). To make sure that p53 is involved in the UA-induced cell growth inhibition and apoptosis, we analyzed the effect of UA on the expression level of p53 in 143B cells. The results showed that both mRNA and protein level of p53 are increased by UA (Fig. 6A and B). Although Wnt/β-catenin signaling is tightly modulated by the Axin/APC/GSK3β complex (50), the level of β-catenin can also be negatively regulated by p53 (29,49). Furthermore, the downregulation of β-catenin induced by p53 was accompanied with the inhibition of its transcription potential (49). So we employed PFT-α, a p53 inhibitor, to determine whether p53 mediates the inhibition of Wnt/β-catenin signaling induced by UA. PFT-α was verified to effectively enhance the expression of β-catenin in gastric adenocarcinoma cells (51). However, a converse observation that PFT-α decreases the protein level of β-catenin in WB-F344 cells was reported in another study (52). These findings suggested that the effects of PFT-α on β-catenin may be cell type-specific. Our results indicated that PFT-α can effectively upregulate the expression of β-catenin, as well as the targets of Wnt/β-catenin signaling in 143B OS cells (Fig. 6C). We further analyzed the effect of p53 inactivation by PFT-α on cell proliferation in 143B OS cells, and found that PFT-α promotes the growth of 143B cells and attenuates the anti-proliferative effects of UA. Hence, the inhibitory effects of UA on Wnt/β-catenin signaling may be mediated by upregulating p53 partly in 143B cells. Taken together, our data suggested that UA can be used as an effective chemotherapy agent for human OS. The anti-tumor activity of UA on OS may be mediated by inactivating Wnt/β-catenin signaling through upregulating p53. However, the exact molecular mechanisms through which UA upregulates p53 need to be further investigated.

Acknowledgements

We thank Dr Tong-Chuan He (University of Chicago, IL, USA) for providing recombinant adenoviruses and pTOP-luc plasmid. This study was supported by a research grant from the National Natural Science Foundation of China (grant nos. NSFC 81372120 and 81572226 to Bai-Cheng He).

References


